{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:46:01Z","timestamp":1755225961034,"version":"3.43.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"TerSera","award":["Pro00076418"],"award-info":[{"award-number":["Pro00076418"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Nausea and vomiting remain feared cancer treatment-related side effects. Antiemetic guideline trials exclude malignant glioma patients. In patients receiving radiation with concurrent temozolomide, chemoradiation-induced nausea; vomiting (cRINV) rates are 35% and 26%, respectively, which reduce quality of life, treatment adherence, and cancer control.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This randomized phase-II open-label trial, evaluated efficacy, patient preference, and satisfaction of ondansetron (short-acting 5HT3-RA; 3 h-half-life) monotherapy versus rolapitant (long-acting NK1-RA; 180 h-half-life) plus ondansetron in preventing cRINV during 6 weeks of temozolomide (75 mg\/m2\/day \u00d7 42 day) with radiation. Fifty-three eligible patients were randomized to Sequence-A (ondansetron-8 mg days: 1\u201342, day 22 rolapitant-180 mg) or Sequence-B (rolapitant day 1 plus daily ondansetron). Primary endpoint was percentage achieving cRINV-complete response (no vomiting\/antiemetic rescue) during the first 2 weeks of radiation. Secondary endpoints: cRIN\/cRIV rates, preference\/satisfaction for rolapitant\/ondansetron, toxicity, and adherence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-eight (Sequence-A: 25; Sequnce-B: 23) initiated chemoradiation. Mean age\u2005=\u200553, 58% male, 73% Karnofsky performance status (KPS)\u2005&amp;gt;\u200590%, and 73% glioblastoma. During first 2 weeks of radiation, cRINV-CR was 57% with ondansetron and 74% receiving rolapitant\/ondansetron (P\u2005=\u2005.27). Patient-reported 6-week cRINV-CR was 55% for both arms. First 2-week cRIN rates (38% Sequence-A; 32% Sequence-B) were more than cRIV rates (19% Sequence-A; 0% Sequence-B). Patients receiving ondansetron alone vomited more during the first 2 weeks and overall (26%) than with rolapitant\/ondansetron (11%). Among 35 completers, 20% preferred rolapitant\/ondansetron, 60% preferred ondansetron, and 20% had no preference (P\u2005=\u2005.0004). Adverse-events attributable to antiemetics were grade 1\u20132.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>No difference was found in cRINV-CRs between the first 2-week treatments or overall satisfaction. Although not a positive study, less vomiting occurred with rolapitant\/ondansetron. While patients prefer ondansetron monotherapy, most perceived better effectiveness with rolapitant\/ondansetron.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/nop\/npaf014","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T23:18:00Z","timestamp":1737847080000},"page":"618-630","source":"Crossref","is-referenced-by-count":0,"title":["Phase II randomized glioma study to evaluate efficacy and satisfaction of rolapitant plus ondansetron in preventing chemoradiation-induced nausea and vomiting"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4004-7834","authenticated-orcid":false,"given":"Mary Lou","family":"Affronti","sequence":"first","affiliation":[{"name":"Duke University School of Nursing, Duke University , Durham, North Carolina ,","place":["USA"]},{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mallika P","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Duke University Hospital , Durham, North Carolina ,","place":["USA"]},{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin K","family":"Severance","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Loughlin","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Bradbury","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E","family":"Herndon","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra","family":"Boyd","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4372-5533","authenticated-orcid":false,"given":"Eric S","family":"Lipp","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-032X","authenticated-orcid":false,"given":"Henry S","family":"Friedman","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annick","family":"Desjardins","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret O","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5110-3868","authenticated-orcid":false,"given":"Katherine B","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"issue":"12 Suppl 2","key":"2025081316521455200_CIT0001","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/neuonc\/noab200","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014\u20132018","volume":"23","author":"Ostrom","year":"2021","journal-title":"Neuro Oncol."},{"issue":"10","key":"2025081316521455200_CIT0002","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"5","key":"2025081316521455200_CIT0003","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"840","key":"2025081316521455200_CIT0004","first-page":"1","article-title":"Real-world evidence in glioblastoma: Stupp\u2019s regimen after a decade","volume":"10","author":"Lakomy","year":"2020","journal-title":"Front Oncol."},{"issue":"7","key":"2025081316521455200_CIT0005","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3346\/jkms.2014.29.7.980","article-title":"Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea","volume":"29","author":"Bae","year":"2014","journal-title":"J Korean Med Sci."},{"article-title":"Highlights of prescribing information. TEMODAR (Temozolomide) Caplules, Temodar\u00ae (temozolomide) for injection, Label - Accessdata.feda.gov","year":"2015","author":"Administration TUSFaD","key":"2025081316521455200_CIT0006"},{"issue":"5","key":"2025081316521455200_CIT0007","first-page":"2229","article-title":"Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide","volume":"28","author":"Patel","year":"2020","journal-title":"Supportive Care Cancer"},{"issue":"14","key":"2025081316521455200_CIT0008","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting","volume":"374","author":"Navari","year":"2016","journal-title":"N Engl J Med."},{"issue":"Suppl 1","key":"2025081316521455200_CIT0009","first-page":"5","article-title":"CINV: still troubling patients after all these years","volume":"26","author":"Aapro","year":"2018","journal-title":"Supportive Care Cancer."},{"issue":"6","key":"2025081316521455200_CIT0010","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol."},{"issue":"2","key":"2025081316521455200_CIT0011","doi-asserted-by":"crossref","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"year":"2024","author":"(NCCN\u00ae) NCCN","key":"2025081316521455200_CIT0012"},{"issue":"24","key":"2025081316521455200_CIT0013","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol."},{"issue":"2","key":"2025081316521455200_CIT0014","first-page":"557","article-title":"Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses","volume":"26","author":"Clark-Snow","year":"2018","journal-title":"Supportive Care Cancer"},{"issue":"7","key":"2025081316521455200_CIT0015","first-page":"1897","article-title":"Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice","volume":"22","author":"Affronti","year":"2014","journal-title":"Supportive Care Cancer"},{"issue":"7","key":"2025081316521455200_CIT0016","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1002\/cam4.1560","article-title":"Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy","volume":"7","author":"Navari","year":"2018","journal-title":"Cancer Med."},{"issue":"10","key":"2025081316521455200_CIT0017","first-page":"4365","article-title":"Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ)","volume":"24","author":"Affronti","year":"2016","journal-title":"Supportive Care Cancer"},{"issue":"11","key":"2025081316521455200_CIT0018","doi-asserted-by":"crossref","first-page":"698","DOI":"10.2176\/nmc.oa.2016-0177","article-title":"Combination of palonosetron, aprepitant, and dexamethasone effectively controls chemotherapy-induced nausea and vomiting in patients treated with concomitant temozolomide and radiotherapy: results of a prospective study","volume":"56","author":"Matsuda","year":"2016","journal-title":"Neurol Med Chir (Tokyo)."},{"issue":"2","key":"2025081316521455200_CIT0019","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/annonc\/mdx748","article-title":"New antiemetics: facing the current challenge","volume":"29","author":"Scotte","year":"2018","journal-title":"Ann Oncol."},{"issue":"8","key":"2025081316521455200_CIT0020","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"2","key":"2025081316521455200_CIT0021","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jpainsymman.2006.10.018","article-title":"Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool","volume":"34","author":"Molassiotis","year":"2007","journal-title":"J Pain Symptom Manage."},{"issue":"11","key":"2025081316521455200_CIT0022","first-page":"1213","article-title":"A review of patient self-report tools for chemotherapy-induced nausea and vomiting","volume":"16","author":"Brearley","year":"2008","journal-title":"Supportive Care Cancer"},{"issue":"36","key":"2025081316521455200_CIT0023","first-page":"1","article-title":"Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes."},{"issue":"12","key":"2025081316521455200_CIT0024","first-page":"1","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes."},{"issue":"Suppl 1","key":"2025081316521455200_CIT0025","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1111\/j.1524-4733.2005.00066.x","article-title":"Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers","volume":"8","author":"Atkinson","year":"2005","journal-title":"Value Health."},{"author":"National Cancer Institute CTEP","key":"2025081316521455200_CIT0026","article-title":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03"},{"issue":"3","key":"2025081316521455200_CIT0027","first-page":"783","article-title":"Radiation-induced nausea and vomiting: a comparison between MASCC\/ESMO, ASCO, and NCCN antiemetic guidelines","volume":"27","author":"McKenzie","year":"2019","journal-title":"Supportive Care Cancer"},{"issue":"suppl 5","key":"2025081316521455200_CIT0028","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol."},{"issue":"1","key":"2025081316521455200_CIT0029","first-page":"267","article-title":"MASCC\/ESMO antiemetic guidelines: introduction to the 2016 guideline update","volume":"25","author":"Molassiotis","year":"2017","journal-title":"Supportive Care Cancer"},{"volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Antiemesis","year":"2022","author":"National Comprehensive Cancer Network [NCCN]","key":"2025081316521455200_CIT0030"},{"issue":"2","key":"2025081316521455200_CIT0031","doi-asserted-by":"crossref","first-page":"104","DOI":"10.21037\/apm.2016.12.01","article-title":"Prophylaxis of radiation-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Li","year":"2017","journal-title":"Ann Palliative Med"},{"issue":"1","key":"2025081316521455200_CIT0032","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijrobp.2010.08.060","article-title":"Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials","volume":"82","author":"Salvo","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2025081316521455200_CIT0033","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/CMAR.S97543","article-title":"Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting","volume":"9","author":"Rapoport","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"9","key":"2025081316521455200_CIT0034","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2176\/nmc.oa.2014-0413","article-title":"Profile analysis of chemotherapy-induced nausea and vomiting in patients treated with concomitant temozolomide and radiotherapy: results of a prospective study","volume":"55","author":"Matsuda","year":"2015","journal-title":"Neurol Med Chir (Tokyo)."},{"issue":"1","key":"2025081316521455200_CIT0035","first-page":"vdab035","article-title":"The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment","volume":"3","author":"Mrugala","year":"2021","journal-title":"Neurooncol Adv."},{"issue":"329","key":"2025081316521455200_CIT0036","first-page":"1","article-title":"Patient-related risk factors for chemotherapy-induced nausea and vomiting: a systematic review","volume":"11","author":"Mosa","year":"2020","journal-title":"Front Pharmacol."},{"issue":"2","key":"2025081316521455200_CIT0037","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med."},{"issue":"6","key":"2025081316521455200_CIT0038","first-page":"479","article-title":"Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center","volume":"6","author":"Patil","year":"2019","journal-title":"Neurooncol Pract."},{"key":"2025081316521455200_CIT0039","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa215.730","article-title":"Olanzapine for refractory chemotherapy-induced nausea and vomiting in malignant glioma patients","author":"Patel","year":"2020"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npaf014\/61660846\/npaf014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/4\/618\/61660846\/npaf014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/12\/4\/618\/61660846\/npaf014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T20:52:24Z","timestamp":1755118344000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/12\/4\/618\/7985347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,28]]},"published-print":{"date-parts":[[2025,8,13]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npaf014","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"type":"print","value":"2054-2577"},{"type":"electronic","value":"2054-2585"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,1,28]]}}}